177 related articles for article (PubMed ID: 11520475)
1. Treatment of the agitation of late-life psychosis and Alzheimer's disease.
Salzman C
Eur Psychiatry; 2001 Jan; 16 Suppl 1():25s-28s. PubMed ID: 11520475
[TBL] [Abstract][Full Text] [Related]
2. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
3. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
[TBL] [Abstract][Full Text] [Related]
4. Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions.
Wragg RE; Jeste DV
Psychiatr Clin North Am; 1988 Mar; 11(1):195-213. PubMed ID: 2898133
[TBL] [Abstract][Full Text] [Related]
5. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
Kirbach S; Simpson K; Nietert PJ; Mintzer J
Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic treatment of psychosis and agitation in the elderly.
Daniel DG
J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
De Deyn PP; Eriksson H; Svensson H;
Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
[TBL] [Abstract][Full Text] [Related]
8. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
10. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
[TBL] [Abstract][Full Text] [Related]
11. Dementia update. Pharmacologic management of agitation and psychosis in older demented patients.
Zaraa AS
Geriatrics; 2003 Oct; 58(10):48-50, 52-3. PubMed ID: 14569642
[No Abstract] [Full Text] [Related]
12. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Schneider LS; Tariot PN; Lyketsos CG; Dagerman KS; Davis KL; Davis S; Hsiao JK; Jeste DV; Katz IR; Olin JT; Pollock BG; Rabins PV; Rosenheck RA; Small GW; Lebowitz B; Lieberman JA
Am J Geriatr Psychiatry; 2001; 9(4):346-60. PubMed ID: 11739062
[TBL] [Abstract][Full Text] [Related]
13. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial.
Schneider LS; Ismail MS; Dagerman K; Davis S; Olin J; McManus D; Pfeiffer E; Ryan JM; Sultzer DL; Tariot PN
Schizophr Bull; 2003; 29(1):57-72. PubMed ID: 12908661
[TBL] [Abstract][Full Text] [Related]
14. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
Lopez OL; Becker JT; Chang YF; Sweet RA; Aizenstein H; Snitz B; Saxton J; McDade E; Kamboh MI; DeKosky ST; Reynolds CF; Klunk WE
Am J Psychiatry; 2013 Sep; 170(9):1051-8. PubMed ID: 23896958
[TBL] [Abstract][Full Text] [Related]
15. A structured trial of risperidone for the treatment of agitation in dementia.
Lavretsky H; Sultzer D
Am J Geriatr Psychiatry; 1998; 6(2):127-35. PubMed ID: 9581208
[TBL] [Abstract][Full Text] [Related]
16. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease.
Devanand DP; Pelton GH; Cunqueiro K; Sackeim HA; Marder K
Int J Geriatr Psychiatry; 2011 Sep; 26(9):937-43. PubMed ID: 21845596
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic interventions for psychosis and agitation in neurodegenerative diseases: evidence about efficacy and safety.
Weintraub D; Katz IR
Psychiatr Clin North Am; 2005 Dec; 28(4):941-83, ix-x. PubMed ID: 16325736
[No Abstract] [Full Text] [Related]
18. The utility of intramuscular ziprasidone in the management of acute psychotic agitation.
Mendelowitz AJ
Ann Clin Psychiatry; 2004; 16(3):145-54. PubMed ID: 15517847
[TBL] [Abstract][Full Text] [Related]
19. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
20. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Tune LE
J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
